1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Unichem Laboratories Limited

Unichem Laboratories Limited

488.15
INR
-14.00
(-2.79%)
43.28EPS
10.62P/E
32.39BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
125.15
132.48
146.75
74.07
85.42
159.58
149.08
169.01
177.26
184.97
246.8
293.23
306.71
327.88
Basic EPS, GAAP
18.69
8.31
11.9
11.96
280.59
-3.38
-8.55
4.88
4.7
-28.72
-13.32
19.53
35.91
43.3
Free Cash Flow per Basic Share
-1.91
-0.06
-5.49
-8.99
-29.98
-74.2
-52.03
-36.19
-54.91
-18.38
-1.21
-20.51
-16.96
- -
Dividend per Share
8.44
3.95
4.77
0.08
3.63
6.02
4.83
4.07
4.03
4.01
0.03
0.05
0.05
- -
Book Value per Share
90.11
97.98
105.05
117.04
381.03
372.23
359.54
363.16
371.9
345.9
346.32
348.07
385.97
- -
Tangible Book Value per Share
89.76
97.65
104.72
116.69
380.75
371.98
359.32
362.94
371.68
345.68
338.1
345.19
384.71
- -
Basic Weighted Avg Shares
91
91
91
91
91
70
70
70
70
70
70
70
70
70
Sales/Revenue/Turnover
11,334
12,018
13,327
6,730
7,747
11,228
10,496
11,899
12,480
13,024
17,376
20,645
21,594
23,079
Operating Margin (%)
11.65
5.04
9.39
-12.49
-23
-12.13
-12.48
0.61
-0.87
-11.95
-2.09
6.8
2.94
4.56
Depreciation Expense
457
413
388
452
518
674
817
844
912
1,134
1,232
1,246
1,251
1,233
Net Income, GAAP
1,693
754
1,081
1,087
25,449
-238
-602
343
331
-2,022
-938
1,375
2,528
3,048
Effective Tax Rate (%)
25.12
2.75
21.32
- -
- -
- -
- -
33.32
- -
- -
- -
11.04
13.52
13.02
Profit Margin (%)
14.94
6.27
8.11
16.15
328.49
-2.12
-5.73
2.88
2.65
-15.53
-5.4
6.66
11.71
13.21
Working Capital
3,504
3,745
3,570
3,558
18,730
15,355
11,197
8,716
10,928
9,489
10,057
10,375
13,114
- -
LT Debt
246
203
230
4
3
- -
185
143
1,036
751
624
860
651
- -
Total Equity
8,166
8,894
9,543
10,636
26,801
26,199
25,314
25,568
26,184
24,353
24,383
24,506
27,174
- -
Return on Invested Capital (%)
13.98
6.68
10.08
- -
- -
- -
- -
0.17
- -
- -
- -
4.49
7.4
- -
Return on Capital (%)
21.5
8.93
11.6
- -
- -
- -
- -
1.38
- -
- -
- -
5.57
9.14
- -
Return on Common Equity (%)
21.94
8.84
11.73
10.77
135.96
-0.9
-2.34
1.35
1.28
-8
-3.85
5.63
9.78
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
4,350
- -
LT Borrowings
- -
391
- -
LT Finance Leases
- -
260
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
70
70
70
Market Capitalization
31,074
20,682
32,387

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
21,973
- -
Cash, Cash Equivalents & STI
- -
2,991
- -
Accounts Receivable, Net
- -
8,286
- -
Inventories
- -
9,750
- -
Total Current Liabilities
- -
8,859
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
4,350
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.57%
1.39%
10.89%
Free Cash Flow
179.17%
292.63%
-17.3%
Net Income, GAAP
120.54%
-186.36%
83.86%
Sales/Revenue/Turnover
8.35%
13.21%
4.6%
Total Cash Common Dividend
450.32%
-5.99%
8.82%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
4,833
5,074
5,331
5,872
20,645
2026
5,266
5,790
5,212
5,751
21,594
2027
6,326
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.29
3.5
8.22
7.52
19.53
2026
-1.49
-1.69
37.54
1.55
35.91
2027
5.89
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
0.05
2026
- -
- -
- -
- -
0.05
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
P. Kalipada Bhattacharyya
Full Time Employees
2,815
Sector
Health technology
Industry
Pharmaceuticals: major
Address
47, Kandivli Industrial Estate Mumbai MA India 400067
IPO Date
Jan 10, 1995
Website
unichemlabs.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Unichem Laboratories Limited operates as a pharmaceutical enterprise, engaging in the worldwide production and distribution of medicinal compounds. Now a subsidiary of IPCA Laboratories Ltd, the company delivers finished dosage forms that cater to diverse therapeutic needs, encompassing areas such as digestive health, cardiovascular conditions, diabetes, mental health, neurological disorders, anti-bacterial and anti-infective treatments, and pain relief. Additionally, it develops and supplies active pharmaceutical ingredients and offers comprehensive contract manufacturing services. Established in 1944, the firm is based in Mumbai, India.